Latest News

Emergency gout admission increase is ‘call to arms’


 

AT RHEUMATOLOGY 2018


After patients’ initial referral to the clinic, they are followed up by the clinic every month until their serum urate levels are below the 0.3 mmol/L target. They can then be discharged and monitored by their family physician.

Postdischarge, Dr. Whiteman and her colleagues found that 22 (76%) of the 29 patients who had met their target levels of serum uric acid later had serum uric acid tested at least once, showing an average level of 0.29 mmol/L at follow-up. This reassuring result occurred perhaps because of a majority of patients (79%) who were still being prescribed, and presumably taking, urate-lowering therapy. Seven patients did not undergo follow-up serum uric acid testing because they had died (one), were in the hospital (one), were not taking medication because they had made diet or lifestyle changes (three), or had their treatment on hold (two).

“I think the gout clinic has been a success; it has addressed barriers to optimal management through education of the patient,” Dr. Whiteman said.

Both presenters had nothing to disclose.

Pages

Recommended Reading

FDA approves once-daily treatment for hyperuricemia in gout
MDedge Rheumatology
Allopurinol extension trial backs treat-to-target approach in gout
MDedge Rheumatology
Febuxostat prevents early gout flares
MDedge Rheumatology
Gout incidence is intertwined with serum urate, but only up to a point
MDedge Rheumatology
FDA: Febuxostat may have increased heart-related death risk
MDedge Rheumatology
Higher water intake linked to less hyperuricemia in gout
MDedge Rheumatology
Rheumatology 911: Inside the rheumatologic emergency
MDedge Rheumatology
Health disparities in rural America: Chronic conditions
MDedge Rheumatology
Febuxostat increases cardiovascular mortality in CARES trial
MDedge Rheumatology
Allopurinol dose not escalated enough to reduce mortality
MDedge Rheumatology

Related Articles